News

ATCC Hires New Chief Commercial Officer

ATCC, the world’s premier biological materials management and standards organization, today announced it has hired Greg Ballish as its new Chief Commercial Officer. In his role, Ballish will head ATCC’s sales and marketing operations and partner with Ruth Cheng, Ph.D., Chief Innovation and Strategy Officer and Vice President of Corporate Development of ATCC, to oversee the corporate business and commercial center. As part of the executive leadership team, Ballish will focus on growing the company’s global footprint and reinforcing ATCC’s position as the de facto leader in biological resources.

“We are fortunate to add Greg’s considerable experience and inclusive management style to our executive team, and we look forward to seeing the impact of his commercial leadership,” said Raymond H. Cypess, DVM, Ph.D., Chairman and CEO of ATCC. “In his role, Greg will ensure that we remain a customer-centric organization and continue our commitment to exceeding expectations and fostering long-lasting partnerships with the institutions and organizations we serve.”

Ballish brings an extensive sales, marketing and operations background in the diagnostics, pharmaceuticals, medical devices, transfusion medicine and medical distribution markets to ATCC. He has guided organizations to top market share positions and held key leadership sales and marketing roles for companies including Abbott Labs, DuPont, Johnson & Johnson, LabCorp, LGC Clinical Diagnostics, Meridian Bioscience, Terumo BCT and the American Red Cross. Ballish holds a Master of Business Administration from Arizona State University and a Bachelor of Science in finance from Miami University.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and